Clinical Conundrum: When, how to treat colorectal cancer in the elderly

Even as scientists plumb deep into cells and molecules to understand cancer, there are many immediate and “real-life” questions that researchers and clinicians are discussing at the 2013 annual ASCO meeting (American Society of Clinical Oncology). One of the biggest puzzles for colorectal cancer is how to best treat the elderly, especially those with stages II…  Read More

New Cancer Drug Zaltrap Discounted by 50%

By Curt Pesman and Mary Miller In an unusual move, sanofi pharmaceutical company has instituted a 50 percent discount, effective immediately, on its latest cancer drug Zaltrap.  The reason for the sharp price drop, company officials said, was “market resistance” to the initial price. Zaltrap was approved in August by the FDA for second-line treatment for metastatic…  Read More

Memorial Sloan-Kettering Will Not Offer Zaltrap

Memorial Sloan-Kettering Cancer Center made a very public announcement—and explanation—today in a New York Times op-ed about why they will not offer the new drug Zaltrap® (ziv-aflibercept) to its metastatic colorectal cancer patients. The authors, all world-renowned cancer specialists at the world’s oldest cancer center, in an op-ed headlined “In Cancer Care, Cost Matters,” essentially challenged other cancer centers…  Read More

Participants Needed for Rectal Cancer Surgery Trial

Approximately 80 more participants are needed for a multisite, Phase 3 clinical trial comparing laparoscopic-assisted versus conventional surgery in patients with stage IIA, Stage IIIA or stage IIIB rectal cancer.  Eligible participants must have completed their pre-surgery chemotherapy (Xelox™ or fluorouracil-based) and/or pre-surgery radiation therapy within the previous 4 weeks.

FDA Approves Regorafenib for Metastatic CRC

  The FDA today approved the use of the drug regorafenib (brand name Stivarga) for patients whose metastatic colorectal cancer has progressed despite all currently approved treatment regimens. This is the second new drug approved by the FDA recently after a drought of 5 years in approving new treatments for metastatic colorectal cancer (mCRC). Regorafenib was placed…  Read More

Why Do the New Drugs Fail in Adjuvant Chemotherapy?

Some of the most surprising data presented at the GI Symposium in January 2011 in San Francisco was the negative result of the European trial called AVANT. In that clinical trial patients who underwent a curative resection for colon cancer received either FOLFOX or FOLFOX with Avastin® (bevacizumab) treatment after their surgery. Chemotherapy was given over…  Read More